Bliss Family Fund to Advance Cellular Therapies for WM supports investigators conducting trials of novel cellular immunotherapies and immune-redirection strategies to improve WM remissions and disease control.
The application deadline was extended from November 9, 2026, to January 26, 2027.
Funder: International Waldenstrom's Macroglobulinemia Foundation
Due Dates: November 9, 2026 (Inaugural RFP closing) | January 26, 2027 (RFP due)
Funding Amounts: Up to $1,000,000 USD over 2–4 years
Summary: Supports investigator-initiated clinical trials of innovative cellular immunotherapies and immune-redirection strategies for Waldenstrom macroglobulinemia.
Key Information: PIs must hold a doctoral degree and a full-time independent research or academic position at the sponsoring institution.
The Bliss Family and International Waldenstrom's Macroglobulinemia Foundation (IWMF) support investigator-initiated trials of distinctly novel cellular immunotherapies and immune-redirection strategies for Waldenstrom macroglobulinemia (WM). Supported approaches include autologous or allogeneic cell therapies, CAR-T and CAR-NK platforms, bispecific and trispecific immune engagers, next-generation engineered cellular approaches, and rational immune-based combinations.
The program seeks clinically meaningful benefit within 3–5 years, including deeper, more durable remissions, complete responses, MRD-negativity, and improved disease control. Studies should establish clinical proof-of-concept supporting larger trials and future regulatory approval or guideline inclusion. Strategies addressing WM-associated immune dysfunction, T-cell exhaustion, and the immune microenvironment are also of interest, including sequencing approaches and earlier intervention in high-risk populations. Correlative studies are welcome where they strengthen interpretation and inform therapeutic development.